E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Ovarian cancers resistant to platinum based chemotherapy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10016180 |
E.1.2 | Term | Fallopian tube cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066697 |
E.1.2 | Term | Ovarian cancer recurrent |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033128 |
E.1.2 | Term | Ovarian cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate an improvement in Progression Free Survival |
|
E.2.2 | Secondary objectives of the trial |
- Improvement in objective response rate (by RECIST and GCIG CA-125 criteria).
- Overall survival.
- Assessment of proportion of subjects who remain progression-free at 6, 9 and 12 months on the regimen of PCC plus bevacizumab and CA4P compared with PCC plus bevacizumab and placebo.
- To evaluate the safety and tolerability of PCC plus bevacizumab and CA4P compared with PCC plus bevacizumab and placebo, as measured by physical exams, vital signs, laboratory measures, ECG, ECOG performance status and incidence of AEs (using NCI CTCAE version 4.03).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent form (ICF).
2. Age ≥ 18 years (age ≥ 19 years if required by local regulatory authorities).
3. ECOG performance status of 0-1.
4. Histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer in recurrent stage.
5. Platinum-resistant ovarian cancers defined as progression within 6 months of receiving last platinum-based therapy.
6. Received ≥ 1 prior platinum-based regimen.
7. Measurable disease according to RECIST 1.1.
8. LVEF greater than or equal to at least 45% at baseline assessment if subject is receiving pegylated liposomal doxorubicin and/or anthracycline as a concomitant medication.
9. No evidence of active (progressing) brain metastasis (treated brain metastasis allowed with a post-treatment MRI or CT of brain showing no active (progressing) brain metastasis). Treatment of brain metastasis may include surgery, radiosurgery (LINAC, gamma knife) or whole brain irradiation. Surgery for brain metastasis must be > 8 weeks from study entry.
10. Hemoglobin > 9 g/dL without transfusions or growth factors.
11. Adequate bone marrow function in the investigator’s opinion.
12. Adequate hepatic function defined by the following:
− Total bilirubin < 2 x ULN;
− Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN for the referenced lab (< 5 X ULN for subjects with liver metastases).
13. Adequate renal function defined by the following:
− Serum creatinine < 2 X ULN for the referenced lab.
14. Subjects of childbearing potential must have a negative serum pregnancy test prior to study entry and must be practicing a highly effective form of contraception.
15. At least 2 weeks since prior radiotherapy and has recovered from any Grade 3 toxicities.
16. Life expectancy ≥ 12 weeks. |
|
E.4 | Principal exclusion criteria |
1. Subjects who have received prior CA4P therapy.
2. Previously having failed treatment with bevacizumab combined with the intended physician's choice chemotherapy (PCC). Investigators should not select a bevacizumab + PCC combination for the FOCUS trial if the patient has previously failed that same regimen, however they may select a new PCC regimen to combine with bevacizumab.
3. Previous treatment with greater than two chemotherapy treatment regimens.
4. Untreated brain metastasis or leptomeningeal brain metastasis.
5. Solid organ or bone marrow transplant.
6. Primary platinum-refractory disease (defined as progression during or within 1 month of completing patients first platinum-containing regimen).
7. > Grade 2 peripheral neuropathy.
8. Current thrombotic or hemorrhagic disorder/event or history of prior event within 6 months of start of screening.
9. History of prior cerebrovascular event (including transient ischemic attack) within 6 months of start of screening.
10. Recent history (within 6 months of start of screening) of angina pectoris, myocardial infarction (including non-Q wave MI), or NYHA Class III and IV congestive heart failure.
11. History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, benign PR interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG.
12. Known uncontrolled HIV infection.
13. Uncontrolled, clinically significant active infection.
14. Serious non-healing wound, ulcer or bone fracture.
15. Subjects with known hypersensitivity to any of the components of CA4P, paclitaxel, pegylated liposomal doxorubicin or bevacizumab.
16. Subjects who are currently or planning on receiving concurrent investigational therapy or who have received investigational therapy for any indication within 30 days of the first scheduled day of dosing.
17. Subjects with any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subjects ability to provide informed consent, cooperate and participate in the study, or interfere with the interpretation of the study results.
18. Subjects with other invasive malignancies, with the exception of non-melanoma skin cancer, or with previous cancer treatment that contraindicates this protocol therapy within last 5 years.
19. Prior radiation therapy to the pelvis or abdomen within 4 weeks of entry into the study.
20. History of fistula, gastrointestinal (GI) perforation or intra-abdominal abscess, or invasive disease/metastases of the bowel which may increase the risk of GI perforation with bevacizumab treatment.
21. Uncontrolled hypertension:
− Sustained BP greater than 150 mmHg SBP / 100 mmHg DBP.
22. Uncontrolled elevated proteinuria levels in the investigator's opinion.
23. Corrected QT interval ([QTc] Fridericia) > 480 ms.
24. Significant vascular disease or recent peripheral arterial thrombosis.
25. Subjects with active bleeding or pathologic conditions that carry high risk of bleeding.
26. Subjects who are pregnant or lactating.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is PFS, defined as the time from the date of randomization until progressive disease (PD) or death from any cause. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Subjects will be assessed for disease response or progression throughout the study according to RECIST after every 8 weeks using the same imaging method as used during screening (CT scan or MRI). Disease progression will be assessed by the investigator according to RECIST criteria. |
|
E.5.2 | Secondary end point(s) |
Objective response rate (ORR), overall survival OS and the proportion of progression-free subjects. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Germany |
Netherlands |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS - last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |